SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics, oncological research, and dry eye disease, announced today that the Centers for Disease Control and Prevention (CDC) highlighted a study that the Company sponsored on neutralizing antibodies in its recent COVID-19 Science Update: Edition 116.
Using AXIM’s rapid neutralizing antibody test, Dr. Douglas Lake and Alexa Roeder, co-lead authors of the study, reported that 25% of two-dose RNA vaccine recipients did not generate high levels of neutralizing antibodies (<50% neutralization). They called this group “vaccine poor responders.” Fortunately, a third dose converted these vaccine poor responders into strong responders with an average of 20-fold increase in neutralizing antibody levels two to four weeks after their third dose.
“As many as 25% of people do not know they did not make high levels of protective antibodies after their second dose,” said Dr. Lake. “It doesn’t matter which vaccine you get as a third dose, but it does matter that you get a third dose. Everyone has a right to know how well their vaccine worked.”
The preprint featured in the CDC update titled, “Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders”, was published by leading scientists including Dr. Douglas Lake, an associate professor at Arizona State University and Dr. Sergei Svarovsky, AXIM’s Chief Scientific Officer.
“Our research team has been hard at work since the pandemic started to study how we can effectively detect neutralizing antibody levels,” said John Huemoeller, CEO of AXIM Biotech. “I am thankful that the CDC sees value in the work that we have done to understand the vaccine’s impact and hope that they continue to recognize the importance of understanding our levels of neutralizing antibodies as well as the work that AXIM is doing to make that possible for the general public.”
To learn more about AXIM® Biotechnologies, please visit: https://aximbiotech.com/science/covid-19-diagnostic-research/ About AXIM® Biotechnologies Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing the landscape of diagnosis of SARS-CoV-2 (COVID-19), dry eye disease (DED) and Oncological indications. AXIM’s COVID-19 neutralizing antibody test is the first rapid diagnostic test detecting levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the detection of ophthalmological conditions such as DED. For more information, please visit www.AXIMBiotech.com.
Forward-Looking Statements The statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will be successfully shown to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the diagnostic candidate can be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, employer or individual use will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of Axim’s diagnostic products will receive clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test utilizing neutralizing antibodies approved for use and various other factors detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on April 15, 2021 and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
CONTACT Public Relations Kathryn Brown Account Director CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.com
AXIM Corporate 6191 Cornerstone Ct., Ste. 114 San Diego, CA 92121, USA P. 858-923-4422
Investor Relations investors@aximbiotech.com 888-759-0844
Allakos has deep pockets, but its market cap now is roughly equal to its $500 million or so in cash, and it has a new 10-year, $69-per-square-foot lease on its books in San Carlos.
The Food and Drug Administration’s authorization of Pfizer (ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.
Dr. David Katz, preventive medicine specialist and president at the True Health Initiative, reacts to the recent approval of COVID-19 pills from Pfizer and Merck, and how much of a difference the pills will make in combating COVID-19's spread.
Novavax CEO Stanley Erck speaks with Yahoo Finance Live about the efficacy of Novavax vaccines and the path to FDA authorization amid a surge of the Omicron variant.
Shares of Moderna (NASDAQ: MRNA) were down 3% as of 10:53 a.m. ET on Thursday after having been off by as much as 5.9% earlier. This move continued a downward trend that began Monday with concerns easing about the potential impact of the omicron variant of COVID-19. The combination of those study results and the FDA authorizations for oral COVID-19 therapies presents a double whammy for vaccine stocks other than Pfizer.
Here’s what findings show about potential impacts on requirements for students, too.
The small company, formed as the Covid pandemic started to take hold in February 2020, could take its oral drug into a late-stage clinical trial as early as the first half of next year.
What happened Shares of Teladoc Health (NYSE: TDOC) were falling 3.2% as of 2:42 p.m. ET on Wednesday. The decline appeared to be linked to reduced concerns about the impact of the coronavirus omicron variant.
The effects of the trial that began 10 years ago this past summer can still be seen today in the approach biotech companies take to developing drugs for rare diseases.
Keep calm and tick on.
Carrie Deak, 44, first started dealing with cancer when she was 26. She currently has an inoperable brain tumor.
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.
Dr. Monica Gandhi, an infectious diseases doctor and professor of medicine at UCSF, joins Yahoo Finance Live to discuss the Omicron variant of the coronavirus and why hospitalizations should be the metric of success at this point in the pandemic.
A week after eclipsing 10,000 COVID cases, Newport County experienced its highest single-week case total.
A United Kingdom Health Security Agency report published on Thursday suggests that the effectiveness of the COVID-19 booster against symptomatic infections of the omicron variant wanes within 10 weeks.The report included 147,597 delta and 68,489 omicron cases, which were reported between Nov. 27 and Dec. 17. It analyzed the percentage of vaccine effectiveness between reported cases of the two strains in individuals who had received a two-dose...
This month has set up Global Blood Therapeutics for a long-term battle with emerging gene therapies in sickle cell disease.
Health officials have said to wait at least six months between vaccination and getting a booster - but with omicron infections on the rise, many are now saying sooner may be better.
Many adults at high risk of severe disease could take the easy-to-use therapy to avoid hospitalization. It was found to be less effective than a just-approved drug by Pfizer in reducing the risk of hospitalization and death.
U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus.
US drugstore chains CVS and Walgreens are limiting the number of rapid at-home covid-19 test individual customers can buy at one time, in response to a surge in demand ahead of the holidays. With covid infections once again on the rise, likely due to the omicron variant, Americans have scrambled to purchase over-the-counter tests. “We ask that our customers please show patience and understanding as together, we continue to navigate the evolving pandemic environment,” Walgreens president John Standley said yesterday (Dec. 21).